The National Medical Insurance Administration announced the new pharmaceutical catalog at a press conference this morning. The main adjustment criteria for this year's medical insurance catalog include pharmaceuticals newly launched or with revised instructions in the past five years, drugs for rare diseases, pediatric drugs and generic drugs encouraged by the state, as well as essential national medicines.
Through the corresponding procedures, a total of 91 new pharmaceuticals have been added in this adjustment, including: 26 for tumor treatment, 15 for chronic diseases like diabetes, 13 for rare diseases, 7 for anti-infection, 11 chinese patent medicines, 4 for psychiatric treatment, and 21 for other areas.
In this year's negotiation/bidding phase, a total of 117 drugs outside the catalog participated, with 89 negotiating/bidding successfully, a success rate of 76% with an average price reduction of 63%, overall comparable to the year 2023. The new National Medical Insurance Pharmaceutical Catalog will be officially implemented starting next year. Taking into account negotiation price reductions and medical insurance reimbursement factors, it is estimated that by 2025, the burden on patients will be reduced by over 50 billion Chinese yuan.
